Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Johnson and Johnson
Mallinckrodt
Baxter
Moodys

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Litigation Details for Phigenix, Inc. v. Genentech, Inc. (N.D. Cal. 2015)

See Plans and Pricing

« Back to Dashboard

Phigenix, Inc. v. Genentech, Inc. (N.D. Cal. 2015)

Docket   Start Trial Date Filed 2015-03-17
Court District Court, N.D. California Date Terminated 2017-08-23
Cause 28:1338 Patent Infringement Assigned To Beth Labson Freeman
Jury Demand Both Referred To Nathanael M. Cousins
Parties CARLTON DEWITT DONALD; GENENTECH INC; MUSC FOUNDATION FOR RESEARCH DEVELOPMENT; PHIGENIX, INC.
Patents 10,029,011; 7,811,572; 8,080,534; 8,383,122; 9,023,001
Attorneys Ahmed J. Davis; Alana Canfield Mannige; Aldo Noto; Benjamin K Thompson; Carlton DeWitt Donald; Catherine Mary Polizzi; Christopher James Wiener; Christopher Jamieson Kendall; David Christopher Hanson; Edward Vincent King , Jr.; Frank M. Lowrey , IV; George C. Harris; Gregory L. Porter; James J. Cekola; John K. Blake , Jr.; John Murray; John Murray ,; Matthew Alan Chivvis; Matthew Carl Berntsen; Matthew I. Kreeger; Matthew Ian Kreeger; Matthew Mark D'Amore; Michael A. Jacobs; Michael Ye; Paul D. Ackerman; Paul E. Weathington; Ping Wang; Randi Engel Schnell; Robert Alan Gutkin; Sorin Gabriel Zaharia; Tiana Scogin Mykkeltvedt; Xiang Li
Firms Andrews Kurth Kenyon LLP; Andrews Kurth Kenyon, LLP H. TX; Andrews Kurth LLP; Andrews Kurth, Kenyon LLP DC; Andrews Kurth, LLP DC; Bondurant Mixson & Elmore; Carlton DeWitt Donald; David Christopher Hanson; Davis Wright and Tremaine; Davis Wright Tremaine; Fish & Richardson P.C.; Fish & Richardson PC; Fish & Richardson, P.C.; Fish & Richardson, PC- Atlanta; John Murray ,; King & Kelleher LLP; Morrison & Foerster; Morrison & Foerster (CA); Morrison & Foerster LLP; Morrison & Foerster, LLP -S.F. CA; Morrison and Foerster LLP; Paul E. Weathington; Randi Engel Schnell
Link to Docket External link to docket
Small Molecule Drugs cited in Phigenix, Inc. v. Genentech, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in Phigenix, Inc. v. Genentech, Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Phigenix, Inc. v. Genentech, Inc. (N.D. Cal. 2015)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 234 Order ORDER CONSTRUING CLAIMS IN U.S. PATENT NO. 8,080,534. Signed by Judge Beth Labson Freeman on 8/… U.S. PATENT NO. 8,080,534 …infringement of U.S. Patent No. 8,080,534B2 21 (“the ’534 Patent”). The Court…the ’534 Patent. 23 I. BACKGROUND ON THE ’534 PATENT …It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the External link to document
2016-09-22 257 ) cell lines. (See, e.g., id., 10:29-11:18.) The '534 14 patent includes separate claims directed…asserted claims 1, 2, and 8 of U.S. Patent No. 8,080,534 (the “'534 patent”) under 6 35 U.S.C. § 112…of the '534 patent are invalid as a matter of law because the 12 '534 patent’s specification… genes. ('534 17 patent (ECF No. 21-1), 6:22-23.) The '534 patent purports to disclose the…disclosed in 13 the parent patent application. See Manual of Patent Examining Procedure § 201.08 ( External link to document
0000-00-00 290 Order on Motion for Sanctions infringement of U.S. Patent No. 8,080,534 17 (“the ’534 patent”). ECF 21. …expression and thus infringes the ’534 patent. Id. Claim 1 of the ’534 patent is …Plaintiff Phigenix, Inc. (“Phigenix”) brings this patent infringement lawsuit against … 23 claims 1, 2, and 8 of the ’534 patent. ECF 21. Kadcyla comprises the antibody trastuzumab… to its 4 patent portfolio, and informed Genentech of its theory External link to document
0000-00-00 327 Order on Motion for Summary Judgment infringes certain claims of U.S. Patent No. 8,080,534 (“the ’534 patent”) based on Kadcyla, a drug …named inventor on numerous issued and pending patents and patent 25 applications… including the ’534 patent. First Am. Compl. (“FAC”) ¶ 1, ECF 21. The ’534 patent … 27 3 (the ’534 patent). According to Phigenix, the ’534 patent describes and claims methods…cancer. ’534 patent 16 at 6:56-7:15. The ’534 patent also shows that External link to document
0000-00-00 388 Exhibit 1 U.S. Patent No. 7,811,572, (’572 patent), which expires on June 5 26, 2027, and U.S. Patent No. 8,383,122…license its patents to 14 provide “patent protection” for Kadcyla – in other words, patents that Phigenix…534 patent and/or the ’534 patent is invalid. In light of 5 Genentech’s current strong patent position…including 682 days of Patent Term Adjustment). U.S. Patent No. 8,337,856 (’856 patent), 2 which expires… has filed for a Patent Term 9 Extension on the ’856 patent and the ’840 patents. My understanding External link to document
0000-00-00 442 Order on Motion for Miscellaneous Relief including U.S. Patent No. 8,080,534 (“the ’534 patent”). First 27 …on numerous issued patents 26 and pending patent applications, including… of the patent, or that it otherwise plans to take any action that would implicate the patent.” … Am. Compl. (“FAC”) ¶¶ 1, 9, ECF 21. The ’534 patent is titled “Targeting PAX2 for the …Treatment of Breast Cancer.” Ex. A to FAC (“the ’534 patent”), ECF 21-1. Phigenix brought this External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Boehringer Ingelheim
Merck
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.